14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
NUVB vs SNDX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Nuvation Bio Inc. (NUVB) is the stronger overall head-to-head candidate over Syndax Pharmaceuticals, Inc. (SNDX) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). NUVB carries a Unified Composite Score of 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin), whereas SNDX carries 63.9/100 (BUY) at $8.72 (N/M Forward P/E, -61.7% operating margin).
Composite vs. Pillar Nuance: While SNDX currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. NUVB 61.0/100 BUY), NUVB captures the overall institutional head-to-head verdict (6–1 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-61.2% vs. -61.7% operating margin) and revenue trajectory (+242.6% vs. +81.6% YoY).
Technical & Structure Timing Caution: NUVB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile SNDX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $822.0M market capitalization and -61.7% operating margin.
OpEx & R&D Reinvestment59.7% of Rev ($173M)
90D Engineering Disclosures0 Published
Investor FAQ NUVB vs SNDX Key Questions & Quantitative Answers
As of Nov 20, 2026, Nuvation Bio Inc. (NUVB) is the stronger overall head-to-head candidate over Syndax Pharmaceuticals, Inc. (SNDX) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). NUVB carries a Unified Composite Score of 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin), whereas SNDX carries 63.9/100 (BUY) at $8.72 (N/M Forward P/E, -61.7% operating margin). Composite vs. Pillar Nuance: While SNDX currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. NUVB 61.0/100 BUY), NUVB captures the overall institutional head-to-head verdict (6–1 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-61.2% vs. -61.7% operating margin) and revenue trajectory (+242.6% vs. +81.6% YoY). Technical & Structure Timing Caution: NUVB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile SNDX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NUVB leads the Growth & Scale pillar: NUVB posts +242.6% YoY revenue growth and +0.0% YoY earnings growth on $202M TTM revenue (85.8% gross margin, -61.2% operating margin), compared with SNDX at +81.6% YoY revenue growth and +0.0% YoY earnings growth on $290M TTM revenue (-2.0% gross margin, -61.7% operating margin). Across the 8-period historical trajectory (FY2016 to FY2025), NUVB cumulative revenue shifted +500.0% while SNDX shifted +21.4%. In operating R&D and SG&A reinvestment, NUVB deploys N/A (0 90-day corporate R&D disclosures) versus 59.7% of Rev ($173M) (0 disclosures) for SNDX.
SNDX screens cheaper on headline valuation multiples. NUVB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-53.6% FCF margin), whereas SNDX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.2x EV/Revenue (-61.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NUVB (-49.1% ROE) versus SNDX (-426.4% ROE) capital efficiency.
In options market volatility and institutional positioning, NUVB carries 65.2% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 55% Vol realized risk). By comparison, SNDX carries 253.5% implied volatility (41st %ile, Balanced (25th–60th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.59β · 112% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.